UNIVERSI
TÄ
TS-
BIBLIOTHEK
P
ADERBORN
Anmelden
Menü
Menü
Start
Hilfe
Blog
Weitere Dienste
Neuerwerbungslisten
Fachsystematik Bücher
Erwerbungsvorschlag
Bestellung aus dem Magazin
Fernleihe
Einstellungen
Sprache
Deutsch
Deutsch
Englisch
Farbschema
Hell
Dunkel
Automatisch
Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist
gegebenenfalls
nur via VPN oder Shibboleth (DFN-AAI) möglich.
mehr Informationen...
Universitätsbibliothek
Katalog
Suche
Details
Zur Ergebnisliste
Ergebnis 10 von 392
Datensatz exportieren als...
BibTeX
Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition
Cytometry. Part B, Clinical cytometry, 2016-01, Vol.90 (1), p.26-30
Stetler-Stevenson, Maryalice
Paiva, Bruno
Stoolman, Lloyd
Lin, Pei
Jorgensen, Jeffrey L.
Orfao, Alberto
Van Dongen, Jacques
Rawstron, Andy C.
2016
Volltextzugriff (PDF)
Details
Autor(en) / Beteiligte
Stetler-Stevenson, Maryalice
Paiva, Bruno
Stoolman, Lloyd
Lin, Pei
Jorgensen, Jeffrey L.
Orfao, Alberto
Van Dongen, Jacques
Rawstron, Andy C.
Titel
Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition
Ist Teil von
Cytometry. Part B, Clinical cytometry, 2016-01, Vol.90 (1), p.26-30
Ort / Verlag
United States: Blackwell Publishing Ltd
Erscheinungsjahr
2016
Quelle
Wiley-Blackwell Journals
Beschreibungen/Notizen
Background Flow cytometric (FC) detection of minimal residual disease (MRD) in multiple myeloma (MM) is prognostic and predictive of response to therapy. Therefore, standardization of FC MM MRD testing is vital to ensure better and uniform assessment of response to therapy and clinical prognostication. The International Clinical Cytometry Society and European Society for Clinical Cell Analysis, recognizing the need for standardized FC approaches, organized a working group to develop consensus guidelines on good clinical practice in FC MM MRD. Consensus guidelines are presented for specimen quality, staining process, reagent combinations, and the data acquisition process, all key factors in achieving high quality FC MM MRD testing. Methods A group of eight flow cytometrists currently performing FC testing in MM evaluated available literature on FC MM MRD testing. A document presenting best practice was developed and reviewed in successive rounds until consensus was reached. Results/Conclusion The consensus on best practice for detection of MRD in MM is that CD38, CD138, and CD45 are analyzed in combination with CD19, CD56, CD27, CD81, and CD117. Consensus guidelines on acceptable specimen quality, staining procedures, panel design, and data acquisition were developed. © 2015 International Clinical Cytometry Society
Sprache
Englisch
Identifikatoren
ISSN: 1552-4949
eISSN: 1552-4957
DOI: 10.1002/cyto.b.21249
Titel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7511978
Format
–
Schlagworte
Antigens, CD - analysis
,
Antigens, CD - genetics
,
Antigens, CD - immunology
,
Antineoplastic Agents - therapeutic use
,
Data Accuracy
,
flow cytometry
,
Flow Cytometry - standards
,
Humans
,
Immunophenotyping - standards
,
minimal residual disease
,
Multiple Myeloma - diagnosis
,
Multiple Myeloma - drug therapy
,
Multiple Myeloma - genetics
,
Multiple Myeloma - immunology
,
myeloma
,
Neoplasm, Residual - diagnosis
,
Neoplasm, Residual - drug therapy
,
Neoplasm, Residual - genetics
,
Neoplasm, Residual - immunology
,
Plasma Cells - drug effects
,
Plasma Cells - pathology
,
Prognosis
,
Remission Induction
,
Specimen Handling - standards
,
Staining and Labeling - standards
Weiterführende Literatur
Empfehlungen zum selben Thema automatisch vorgeschlagen von
bX